Letrozole Tablet, Film Coated
Product Images NDC 80005-139

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 80005-139). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carnegie Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure001)

A line graph comparing treatment outcomes over 72 months between Letrozole and Tamoxifen. The graph shows the number of patients at risk at various time points and includes event and censoring data for each treatment group. Letrozole is represented by a solid line and Tamoxifen by a dashed line.*

FDA Label Image

Figure 2 (Figure002)

A Kaplan-Meier survival curve comparing progression-free status over time in months between Letrozole 2.5 mg (solid line) and Tamoxifen 20 mg (dashed line). The y-axis represents the proportion of progression-free patients, showing a decline over approximately 54 months for both treatments.*

FDA Label Image

Figure 3 (Figure003)

A survival curve chart comparing the proportion alive over time in months for patients treated first with letrozole versus tamoxifen. The vertical axis represents the fraction alive, and the horizontal axis shows the duration up to 60 months. Two lines illustrate the survival trends for letrozole (solid line) and tamoxifen (dashed line).*

FDA Label Image

Figure 4 (Figure004)

A line chart comparing time to progression in days for different treatment groups, including Letrozole 0.5 mg, Letrozole 2.5 mg, and MA. The x-axis represents time to progression in days, ranging from 0 to 1000, while the y-axis represents the proportion of patients, ranging from 0 to 1. The graph shows decreasing progression over time for each treatment.*

FDA Label Image

Figure 5 (Figure005)

A Kaplan-Meier survival curve chart showing time to progression (in days) on the x-axis and survival probability on the y-axis. It compares three treatment groups: Letrozole 0.5 mg (solid line), Letrozole 2.5 mg (dotted line), and AG (dashed line). The graph displays decreasing survival probabilities over time for each group.*

FDA Label Image

Bottle Label (30 tablets)

Label for Letrozole Tablets, USP 2.5 mg oral film-coated tablets by Carnegie Pharmaceuticals LLC. The label includes dosage strength, directions to see package insert for dosage, storage instructions, NDC 80005-139-08, barcode, and a 2D data matrix area for batch details, lot, expiration, and serial numbers. The package contains 30 tablets.*

FDA Label Image

Bottle Label (90 tablets)

Label for Letrozole Tablets, USP 2.5 mg film-coated oral tablets by Carnegie Pharmaceuticals LLC. The label includes dosage strength, quantity of 90 tablets, storage instructions, RX only designation, and place of manufacture and distribution. Also features a 2D data matrix code and placeholder text for GTIN, lot number, expiration date, and serial number.*

FDA Label Image

Structure (Structure)

Chemical structure of Letrozole, showing its molecular framework including triazole and cyano-substituted phenyl rings as part of its compound structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.